Granted Patent
B2
US 12,377,054 · App. 18/121,527 · Granted Aug 5, 2025
Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
Inventors:
Willem Mulder (Eindhoven, NL); Jordi Ochando (New York, NY); Zahi Fayad (Larchmont, NY); Mounia Braza (New York, NY); Raphaël Duivenvoorden (Gelderland, NL); Francois Fay (New York, NY)
Assignee:
Icahn School of Medicine at Mount Sinai
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods and compositions for inducing long-term tolerance by hybrid nanoparticles are provided. Compositions and formulations comprising hybrid nanoparticles with inherent affinity for innate immune cells are provided.
Claims (18)
1. A method for reducing tissue rejection in a patient in need thereof, the method comprising administering to the patient an effective amount of a composition comprising a high-density lipoprotein (HDL)-derived nanoparticle which comprises an mTOR inhibitor selected from rapamycin or an ester or prodrug thereof, a phospholipid, and an apolipoprotein A-I (apoA-I), wherein the patient has received an allogeneic tissue transplant, and wherein the composition is administered intravenously.
2. The method of claim 1 , wherein the phospholipid is a phosphatidylcholine, a phosphatidylethanolamine, a phosphatidylinositol, a phosphatidylserine, or a ceramide.
3. The method of claim 1 , wherein the phospholipid is dimyristoylphosphatidylcholine (DMPC), soy lecithin, dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dilaurylolyphosphatidylcholine (DLPC), dioleoylphosphatidylcholine (DOPC), dilaurylolylphosphatidylglycerol (DLPG), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG), dioleoylphosphatidylglycerol (DOPG), dimyristoyl phosphatidic acid (DMPA), dipalmitoyl phosphatidic acid (DPPA), dimyristoyl phosphatidylethanolamine (DMPE), dipalmitoyl phosphatidylethanolamine (DPPE), dimyristoyl phosphatidylserine (DMPS), dipalmitoyl phosphatidylserine (DPPS), dipalmitoyl sphingomyelin (DPSP), distearoyl sphingomyelin (DSSP), and mixtures thereof.
4. The method of claim 1 , wherein the HDL-derived nanoparticle comprises 1,2-(dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and 1-myristoyl-2-hydroxy-sn-glycero-3-phosphocholine (MHPC).
5. The method of claim 1 , wherein the mTOR inhibitor is rapamycin.
6. The method of claim 1 , wherein the mTOR inhibitor is a prodrug of rapamycin.
7. The method of claim 1 , wherein the mTOR inhibitor is an ester of rapamycin.
8. The method of claim 1 , wherein the HDL-derived nanoparticle comprises cholesterol.
9. The method of claim 4 , wherein the apoA-I is human apoA-I.
10. The method of claim 4 , wherein the weight ratio of DMPC:MHPC is about 2:1 to about 4:1.
11. The method of claim 10 , wherein the weight ratio of DMPC:MHPC is about 3:1.
12. The method of claim 1 , wherein the HDL-derived nanoparticle is discoidal in shape and has a size from about 10 nm to about 250 nm.
13. The method of claim 1 , wherein the transplanted tissue is lung tissue, heart tissue, kidney tissue, liver tissue, retinal tissue, corneal tissue, skin tissue, pancreatic tissue, intestinal tissue, genital tissue, ovary tissue, bone tissue, tendon tissue, bone marrow, or vascular tissue.
14. The method of claim 13 , wherein the transplanted tissue is an intact organ.
15. The method of claim 1 , further comprising administering to the patient one or more immunosuppressant agents.
16. The method of claim 15 , wherein the immunosuppressant agent is cyclosporine A or FK506.
17. The method of claim 1 , wherein the subject is human.
18. A method for the prophylaxis of tissue rejection in a patient in need thereof, the method comprising administering to the patient an effective amount of a composition comprising a high-density lipoprotein (HDL)-derived nanoparticle which comprises an mTOR inhibitor selected from rapamycin or an ester or prodrug thereof, a phospholipid, and an apolipoprotein A-I (apoA-I)), and wherein the composition is administered intravenously.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 1, 2025
From: MULDER, WILLEM; OCHANDO, JORDI; FAYAD, ZAHI; BRAZA, MOUNIA; DUIVENVOORDEN, RAPHAËL; FAY, FRANCOIS
To: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Reel/Frame 071581/0760 →
Continuity (3)
Division
16097013
Provisional Application
62329676
· Apr 29, 2016
References Cited (400)
US 4406890A
· Tarcsay et al.
· 1983
[cited by applicant]
US 4640911A
· Baschang
· 1987
[cited by applicant]
US 5349060A
· Kao et al.
· 1994
[cited by applicant]
US 5540931A
· Hewitt et al.
· 1996
[cited by applicant]
US 5543158A
· Gref et al.
· 1996
[cited by applicant]
US 5552157A
· Yaai et al.
· 1996
[cited by applicant]
US 5565213A
· Nakamori et al.
· 1996
[cited by applicant]
US 5567434A
· Szoka, Jr.
· 1996
[cited by applicant]
US 5665772A
· Cottens et al.
· 1997
[cited by applicant]
US 5738868A
· Shinkarenko
· 1998
[cited by applicant]
US 5741516A
· Webb et al.
· 1998
[cited by applicant]
US 5795587A
· Gao et al.
· 1998
[cited by applicant]
US 5985890A
· Cottens et al.
· 1999
[cited by applicant]
US 6200985B1
· Cottens et al.
· 2001
[cited by applicant]
US 6440990B1
· Cottens et al.
· 2002
[cited by applicant]
US 7488802B2
· Collins et al.
· 2009
[cited by applicant]
US 7943743B2
· Korman et al.
· 2011
[cited by applicant]
US 8008449B2
· Korman et al.
· 2011
[cited by applicant]
US 8168757B2
· Finnefrock et al.
· 2012
[cited by applicant]
US 8217149B2
· Irving et al.
· 2012
[cited by applicant]
US 8563603B2
· Chavez
· 2013
[cited by applicant]
US 8865644B2
· Cho
· 2014
[cited by applicant]
US 9408829B2
· Lutgens et al.
· 2016
[cited by applicant]
US 20060222652A1
· Sebbel et al.
· 2006
[cited by applicant]
US 20090226525A1
· Rios et al.
· 2009
[cited by applicant]
US 20150182461A1
· Kim et al.
· 2015
[cited by applicant]
US 20190008918A1
· Upmanyu et al.
· 2019
[cited by applicant]
US 20190153443A1
· Fitzgerald et al.
· 2019
[cited by applicant]
US 20190290593A1
· Mulder et al.
· 2019
[cited by applicant]
US 20200253884A1
· Mulder et al.
· 2020
[cited by applicant]
US 20200261591A1
· Mulder et al.
· 2020
[cited by applicant]
US 20200376102A1
· Mulder et al.
· 2020
[cited by applicant]
US 20200376146A1
· Mulder et al.
· 2020
[cited by applicant]
US 20230355537A1
· Mulder et al.
· 2023
[cited by applicant]
US 20240190921A1
· Janssen et al.
· 2024
[cited by applicant]
CN 101096386
· 2008
[cited by applicant]
CN 101888780
· 2010
[cited by applicant]
CN 101903018
· 2010
[cited by applicant]
CN 102027019
· 2011
[cited by applicant]
CN 102178954
· 2011
[cited by applicant]
CN 102264364A
· 2011
[cited by applicant]
CN 103118691
· 2013
[cited by applicant]
CN 103354749
· 2013
[cited by applicant]
CN 103533934
· 2014
[cited by applicant]
CN 103589699A
· 2014
[cited by applicant]
CN 105828834
· 2016
[cited by applicant]
CN 106714836
· 2017
[cited by applicant]
CN 106831614A
· 2017
[cited by applicant]
CN 111971028A
· 2020
[cited by applicant]
EP 0003833
· 1979
[cited by applicant]
EP 0021367
· 1981
[cited by applicant]
EP 0025495
· 1981
[cited by applicant]
EP 0102319
· 1984
[cited by applicant]
EP 0163286
· 1985
[cited by applicant]
EP 0173960
· 1986
[cited by applicant]
EP 0192609
· 1986
[cited by applicant]
EP 0192611
· 1986
[cited by applicant]
JP 5528933
· 1980
[cited by applicant]
JP 58172399
· 1983
[cited by applicant]
JP 2007532134
· 2007
[cited by applicant]
KR 102198900B1
· 2021
[cited by applicant]
WO WO1993010148
· 1993
[cited by applicant]
WO WO1994009010
· 1994
[cited by applicant]
WO WO1995010293
· 1995
[cited by applicant]
WO WO1995016691
· 1995
[cited by applicant]
WO WO1996001645
· 1996
[cited by applicant]
WO WO1996009063
· 1996
[cited by applicant]
WO WO1996041807
· 1996
[cited by applicant]
WO WO1998009989
· 1998
[cited by applicant]
WO WO2003042402
· 2003
[cited by applicant]
WO WO2006053430
· 2006
[cited by applicant]
WO WO2007022474
· 2007
[cited by applicant]
WO WO2008156712
· 2008
[cited by applicant]
WO WO2009051837
· 2009
[cited by applicant]
WO WO2009106999
· 2009
[cited by applicant]
WO WO2010036959
· 2010
[cited by applicant]
WO WO2010047839
· 2010
[cited by applicant]
WO WO2010089411
· 2010
[cited by applicant]
WO WO2011066342
· 2011
[cited by applicant]
WO WO2011082400
· 2011
[cited by applicant]
WO WO2011159877
· 2011
[cited by applicant]
WO WO2011161699
· 2011
[cited by applicant]
WO WO2015079411
· 2015
[cited by applicant]
WO WO2016019333
· 2016
[cited by applicant]
WO WO2016138286
· 2016
[cited by applicant]
WO WO2016154544
· 2016
[cited by applicant]
WO WO2016172146
· 2016
[cited by applicant]
WO WO2016172615A1
· 2016
[cited by applicant]
WO WO2017011685
· 2017
[cited by applicant]
WO WO2017024312
· 2017
[cited by applicant]
WO WO2017106690A1
· 2017
[cited by examiner]
WO WO2017190145
· 2017
[cited by applicant]
WO WO2017205536A2
· 2017
[cited by applicant]
WO WO2018071549
· 2018
[cited by applicant]
WO WO2018187515
· 2018
[cited by applicant]
WO WO2019103998
· 2019
[cited by applicant]
WO WO2023192956
· 2023
[cited by applicant]
Kim et al., ACS Nano, vol. 7, No. 11, 9975-9983 (2013) (Year: 2013).
[cited by examiner]
Office Action in European Appln. No. 22155443.9, mailed on Aug. 28, 2023, 6 pages.
[cited by applicant]
Costello et al., “A Review of the current status and concept of the emerging implications of zinc and zinc transporters in the development of pancreatic cancer,” Pancreatic disorders & therapy, Jan. 2013, 19 pages.
[cited by applicant]
Wang et al., “Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy,” PNAS, Mar. 24, 2020, 117(12):6640-6650.
[cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2023/065166, mailed on Oct. 10, 2024, 10 pages.
[cited by applicant]
Invitation to Pay Additional Fees in International Appln. No. PCT/US2023/065166, mailed on Jul. 14, 2023, 2 pages.
[cited by applicant]
Office Action in Australian Appln. No. 2018370828, mailed on Nov. 8, 2023, 5 pages.
[cited by applicant]
Office Action in Australian Appln. No. 2022204675, dated Aug. 19, 2024, 4 pages.
[cited by applicant]
Office Action in Japanese Appln. No. 2023-060872, mailed on Apr. 16, 2024, 5 pages (with English translation).
[cited by applicant]
Office Action in Japanese Appln. No. 2023-130072, mailed on Sep. 10, 2024, 9 pages (with English translation).
[cited by applicant]
Office Action in Japanese Appln. No. 2023-163975, mailed on Aug. 6, 2024, 4 pages (with English translation).
[cited by applicant]
Cecil Textbook of Medicine, 20th Edition, Bennett et al. (ed), vol. 1, Edition, vol. 1, 1996, pp. 1004-1010.
[cited by applicant]
Gura et al., “Systems for Identifying New Drugs Are Often Faulty,” Science, Nov. 7, 1997, 278:1041-1042.
[cited by applicant]
Johnson et al., “Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials,” British Journal of Cancer, 2001, 84:1424-1431.
[cited by applicant]
Office Action in Colombian Appln. No. 202302783, mailed on Dec. 12, 2024, 28 pages (with Machine translation).
[cited by applicant]
Office Action in Japanese Appln. No. 2023-060872, mailed on Jan. 7, 2025, 6 pages (with English translation).
[cited by applicant]
Office Action in Chinese Appln. No. 202410398398.2, mailed on Nov. 26, 2024, 11 pages (with English translation).
[cited by applicant]
Office Action in Colombian Appln. No. NC2023/0013700, mailed on Nov. 5, 2024, 18 pages (with Machine translation).
[cited by applicant]
Sun, “The Synthesis of Novel Carbonylthiourea, Amide, Imidazo-[2, 1-b]-1, 3, 4-thiadiazole Containing Pyrazole Ring,” Master's e-Journal, Engineering Science and Technology I, 2009, Issue 2, 7 pages (with English abstra…
[cited by applicant]
U.S. Appl. No. 16/097,013, filed Oct. 26, 2018, Willem J. M. Mulder.
[cited by applicant]
U.S. Appl. No. 16/862,564, filed Apr. 30, 2020, Willem J. M. Mulder.
[cited by applicant]
U.S. Appl. No. 16/862,570, filed Apr. 30, 2020, Willem J. M. Mulder.
[cited by applicant]
U.S. Appl. No. 17/743,342, filed May 12, 2022, Willem J. M. Mulder.
[cited by applicant]
U.S. Appl. No. 18/076,759, filed Dec. 7, 2022, Willem J. M. Mulder.
[cited by applicant]
U.S. Appl. No. 18/927,572, filed Oct. 25, 2024, Willem J. M. Mulder.
[cited by applicant]
U.S. Appl. No. 16/863,333, filed Apr. 30, 2020, Willem J. M. Mulder.
[cited by applicant]
U.S. Appl. No. 16/863,438, filed Apr. 30, 2020, Willem J. M. Mulder.
[cited by applicant]
U.S. Appl. No. 18/806,189, filed Aug. 15, 2024, Willem J. M. Mulder.
[cited by applicant]
U.S. Appl. No. 17/698,971 (U.S. Pat. No. 11,859,021), filed Mar. 18, 2022 (Jan. 2, 2024), Henricus Marie Janssen.
[cited by applicant]
U.S. Appl. No. 18/510,323, filed Nov. 15, 2023, Henricus Marie Janssen.
[cited by applicant]
U.S. Appl. No. 18/850,960, filed Sep. 25, 2024, Abraham J. Teunissen.
[cited by applicant]
[No. Author], “Highlights of Prescribing Information - RAPAMUNE (sirolimus) oral solution; RAPAMUNE (sirolimus) tablets, for oral use,” Distributed by Wyeth Pharmaceuticals Inc., Pfizer, revised on Apr. 2017, 56 pages.
[cited by applicant]
[No Author], Rationale of Drug Design, 1st Ed., China Campeering, Chinese Pharmaceutical Science Press, Apr. 1990, pp. 199-200 (Relevance Explained in Chinese Office Action in Chinese Patent Application No. 201880086231…
[cited by applicant]
Adamczyk et al., “Lipase Mediated Hydrolysis of Rapamycin 42-Hemisuccinate Benzyl and Methyl Esters, ” Tetrahedron Letters, 1994, 35(7); 1019-1022.
[cited by applicant]
Ahmed et al., “Immunological memory and protective immunity: understanding their relation, ” Science, 1996, 272(5258):54-60.
[cited by applicant]
Ahonen et al., “The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells,” Nat. Immunol., May 2002, 3(5):451-456.
[cited by applicant]
Anders et al., “HTSeq—a Python framework to work with high-throughput sequencing data,” Sep. 25, 2014, 31(2):166-169.
[cited by applicant]
Andre et al., “CD40L stabilizes arterial thrombi by a β3 integrin-dependent mechanism,” Nature, Mar. 2002, 8(3):247-252.
[cited by applicant]
Arnold et al., “Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis,” The Journal of Experimental Medicine, 2007, 204(5):1057-1069.
[cited by applicant]
Assanga et al., “Cell growth curves for different cell lines and their relationship with biological activities,” Int. J. Biotechnol. Mol. Biol. Res., Aug. 2013, 4(4):60-70.
[cited by applicant]
Auchincloss, “No. tolerance for depletion,” Nature Medicine, 2004, 10:21-23.
[cited by applicant]
Back et al., “Anti-inflammatory therapies for atherosclerosis,” Nature Reviews Cardiology, Feb. 10, 2015, 12:199-211.
[cited by applicant]
Bayle et al., “Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity,” Chemistry & Biology, Jan. 2006, 13(1):99-107.
[cited by applicant]
Bekkering et al., “In Vitro Experimental Model of Trained Innate Immunity in Human Primary Monocytes,” Clinical and Vaccine Immunology, Dec. 2016, 23(12):926-933.
[cited by applicant]
Benichou et al., “Innate immunity and resistance to tolerogenesis in allotransplantation,” Frontiers in Immunology, 2012, 3:73.
[cited by applicant]
Berge et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences, Jan. 1977, 66(1):1-19.
[cited by applicant]
Boussiotis et al., “Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway,” New England Journal of Medicine, 2016, 375:1767-1778.
[cited by applicant]
Braza et al., “Inhibiting Inflammation with Myeloid Cell-Specific Nanobiologics Promotes Organ Transplant Acceptance,” Immunity, 2018, 49, 819-828.
[cited by applicant]
Bregoli et al., “Nanomedicine applied to translational oncology: A future perspective on cancer treatment,” Nanomedicine: Nanotechnology, Biology and Medicine, 2016, 12(1):81-103.
[cited by applicant]
Bricarello et al., “Reconstituted lipoprotein: a versatile class of biologically-inspired nanostructures,” ACS Nano, 2011, 5:42-57.
[cited by applicant]
Brignone et al., “A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells,” Journal of Immunology, Sep. 15, 2007, 179(6):4202-4211.
[cited by applicant]
Brundish et al., “Synthesis of N-[2-
[cited by applicant]
Buffen et al., “Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer,” PLOS Pathog., 2014, 10:e1004485, 10 pages.
[cited by applicant]
Burgess et al., “Immunotherapeutic approaches to sarcoma,” Current Treatment Options in Oncology, 2015, 16(6):1-4.
[cited by applicant]
Cancer.org [online], “Key Statistics for Melanoma Skin Cancer,” Jan. 12, 2022, retrieved on Apr. 18, 2022, retrieved from URL<https://www.cancer.org/cancer/melanoma-skin-cancer/about/key-statistics.html>, 2 pages.
[cited by applicant]
CAS Registry No. 1054609-71-0, STN entry date: Sep. 29, 2008, STN Registry, chemical name unassigned, 1 page.
[cited by applicant]
CAS Registry No. 1054657-07-6, STN entry date: Sep. 29, 2008, STN Registry, chemical name: D-Glutamamide, N-[(8ξ)-N-acetyl-β-muramoy1]-L-alany1-N5-[(1S)-1-methyl-2-(octyloxy)ethyl]-, 1 page.
[cited by applicant]
CAS Registry No. 1135450-63-3, STN entry date: Apr. 16, 2009, STN Registry, chemical name: L-Threonine, N-(N-acetyl-α-muramoyl)-L-valyl-D-α-glutaminyl-L-arginyl-L-prolyl-N6-L-alanyl-L-lysyl-, methyl ester, 1 page.
[cited by applicant]
CAS Registry No. 1135450-66-6, STN entry date: Apr. 16, 2009, STN Registry, chemical name: L-Threonine, N-(N-acetyl-α-muramoyl)-L-valyl-D-α-glutaminy1-L-arginyl-L-prolyl-N6-L-valyl-L-lysyl-, methyl ester, 1 page.
[cited by applicant]
CAS Registry No. 1135450-69-9, STN entry date: Apr. 16, 2009, STN Registry, chemical name: L-Threonine, N-(N-acetyl-α-muramoy1)-L-valyl-D-α-glutaminyl-L-arginyl-L-prolyl-N6-glycyl-L-lysyl-, methyl ester, 1 page.
[cited by applicant]
CAS Registry No. 1135450-72-4, STN entry date: Apr. 16, 2009, STN Registry, chemical name: L-Threonine, N-(N-acetyl-α-muramoyl)-L-alanyl-D-α-glutaminyl-L-arginyl-L-proly1-N6-glycyl-L-lysyl-, methyl ester, 1 page.
[cited by applicant]
CAS Registry No. 1135450-74-6, STN entry date: Apr. 16, 2009, STN Registry, chemical name: L-Threonine, N-(N-acetyl-a-muramoyl)-L-alany1-D-α-glutaminy1-L-arginyl-L-prolyl-N6-L-valyl-L-lysyl-, methyl ester, 1 page.
[cited by applicant]
CAS Registry No. 130279-67-3, STN entry date: Nov. 9, 1990, STN Registry, chemical name: L-Lysine, N-[O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1-→4)-O-(N-acetyl-β-muramosyl)-(1-→4)-O-2-(acetylamino)-2-deoxy-β-D-glu…
[cited by applicant]
CAS Registry No. 130324-95-7, STN entry date: Nov. 9, 1990, STN Registry, chemical name: L-Lysine, N2-[N2-[N-[O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1-→4)-O-2-(acetylamino)-2-deoxy-3-O-[7-(aminocarbonyl)-12- carb…
[cited by applicant]
CAS Registry No. 171669-22-0, STN entry date: Dec. 22, 1995, chemical name: D-Glutamamide, N-[N-acetyl-1-O-(phenylmethyl)-α-muramoyl]-L-alany1-N5-[6-oxo-6-(phenylmethoxy)hexyl]—(9CI), 1 page.
[cited by applicant]
CAS Registry No. 727353-41-5, STN entry date: Aug. 16, 2004, STN Registry, chemical name: L-Arginine, N-(N-acetyl-α-muramoy1)-L-2-aminobutanoyl-D-α-glutaminy1-, methyl ester (9CI), 1 page.
[cited by applicant]
CAS Registry No. 739324-45-9, STN entry date: Sep. 3, 2004, STN Registry, chemical name: D-Glutamamide, N-(N-acetylmuramoy1)-L-alany1-N5-[(7R)-4-hydroxy-4-oxido-10-oxo-7-[(1-oxohexadecyl)oxy]-3,5,9-trioxa-4-phosphapenta…
[cited by applicant]
CAS Registry No. 740048-83-3, STN entry date: Sep. 5, 2004, STN Registry, chemical name: L-Arginine, N-[N-acetyl-1,4,6-tris-O-(1-oxopropy1)-β- muramoyl]-L-2-aminobutanoyl-D-α-glutaminyl-, methyl ester (9CI), 1 page.
[cited by applicant]
CAS Registry No. 74817-61-1, STN entry date: Nov. 16, 1984, STN Registry, chemical name: D-Glutamine, N-(N-acetylmuramoy1)-L-alanyl-, butyl ester, 1 page.
[cited by applicant]
CAS Registry No. 760134-41-6, STN entry date: Oct. 10, 2004, STN Registry, chemical name: L-Arginine, N-(N-acetyl-1,4,6-tri-O-acetyl-α-muramoyl)-L-2-aminobutanoyl-D-a-glutaminy1-, methyl ester (9CI), 1 page.
[cited by applicant]
CAS Registry No. 768320-98-5, STN entry date: Oct. 24, 2004, STN Registry, chemical name: L-Arginine, N-(N-acetyl-ß-muramoyl)-L-2-aminobutanoyl-D-a-glutaminy1-, methyl ester (9CI), 1 page.
[cited by applicant]
CAS Registry No. 776255-37-9, STN entry date: Nov. 8, 2004, STN Registry, chemical name: L-Arginine, N-(N-acetyl-1,4,6-tri-O-acetyl-β-muramoyl)-L-2-aminobutanoyl-D-a-glutaminyl-, methyl ester (9CI), 1 page.
[cited by applicant]
CAS Registry No. 777018-44-7, STN entry date: Nov. 8, 2004, STN Registry, chemical name: L-Arginine, N-[N-acetyl-1,4,6-tris-O-(1-oxopropyl)-α-muramoyl]-L-2-aminobutanoyl-D-a-glutaminy1-, methyl ester, (9CI), 1 page.
[cited by applicant]
CAS Registry No. 78113-36-7, STN entry date: Nov. 16, 1984, STN Registry, chemical name: L-Lysine, N-(N-acetylmuramoyl)-L-alanyl-D-α-glutaminy1-N6-(1-oxooctadecyl)-, 1 page.
[cited by applicant]
Cdc.gov [online], “Heart Disease Facts,” Mar. 2017, retrieved on Mar. 24, 2022, retrieved from URL<https://www.cdc.gov/heartdisease/facts.htm# :˜: text=Heart%20Disease%20in%20the%20United%20States&text=One%20person%20di…
[cited by applicant]
Chambenoit et al., “Specific Docking of Apolipoprotein A-I at the Cell Surface Requires a Functional ABCA1 Transporter,” The Journal of Biological Chemistry, Mar. 2001, 276(13):9955-9960.
[cited by applicant]
Chatzigeorgiou et al. “Blocking CD40-TRAF6 signaling is a therapeutic target in obesity associated insulin resistance,” Proc. Natl. Acad. Sci. U.S.A., Feb. 2014., 18, 2014, 111(7):2685-91.
[cited by applicant]
Cheng et al. “mTOR/HIFla-Mediated Aerobic Glycolysis as Metabolic Basis for Trained Immunity,” Science, Sep. 26, 2014, 345(6204):1-10.
[cited by applicant]
Chinetti-Gbaguidi et al., “Macrophage subsets in atherosclerosis,” Nature, Jan. 2015, 12:10-17.
[cited by applicant]
Conde et al., “DC-SIGN+ Macrophages Control the Induction of Transplantation Tolerance, ” Immunity, Jun. 16, 2015, 42:1143-1158.
[cited by applicant]
Corry et al., “Primarily vascularized allografts of hearts in mice,” Transplantation, 1973, 16(4):343-350.
[cited by applicant]
Davankov, “International Union of Pure and Applied Chemistry—Analytical Chemistry Division Commission on Separation Methods in Analytical Chemistry (V3)—Analytical Chiral Separation Methods,” Pure and Applied Chemistry,…
[cited by applicant]
Demeester et al., “Synthesis of Functionalized N-Acetyl Muramic Acids To Probe Bacterial Cell Wall Recycling and Biosynthesis,” J. Am. Chem. Soc., 2018, 140(30):9458-9465.
[cited by applicant]
Demir et al., “Cancer screening of renal transplant patients undergoing long-term immnunosuppressive therapy,” Transplantation Proceedings, Jun. 2015, 47(5):1413-1417.
[cited by applicant]
Demirkiran et al., “Conversion From Calcineurin Inhibitor to Mycophenolate Mofetil-Based Immunosuppression Changes the Frequency and Phenotype of CD4+ FOXP3
[cited by applicant]
Ding et al., “Enalapril inhibits tubulointerstitial inflammation and NLRP3 inflammasome expression in BSA-overload nephropathy of rats,” Acta Pharmacologica Sinica (2014) 35: 1293-1301.
[cited by applicant]
Dotti, “Blocking PD-1 in cancer immunotherapy,” Blood, Aug. 20, 2009, 114(8): 1457-1459.
[cited by applicant]
Duarte et al., “Abstract CT099: A phase I study of intralesional
[cited by applicant]
Duivenvoorden et al., “A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation,” Jan. 20, 2014, 5(3065):12 pages.
[cited by applicant]
Dutta et al., “Myocardial infarction accelerates atherosclerosis,” Nature, Jul. 19, 2012, 487(7407):325-329.
[cited by applicant]
Dzierzbicka et al., “New conjugates of muramyl dipeptide and nor-muramyl dipeptide linked to tuftsin and retro-tuftsin derivatives significantly influence their biological activity,” Pharmacological Reports, 2012, 64:21…
[cited by applicant]
Dzierzbicka et al., “Synthesis of Conjugates of Muramyl Dipeptide and nor-Muramyl Dipeptide with Retro-Tuftsin (Arg-Pro-Lys-ThrOMe) as Potential Immunostimulants,” Polish Journal of Chemistry, 2004, 78:409-416.
[cited by applicant]
Dzierzbicka et al., “Synthesis of new conjugates of MDP and nor-MDP with retro-tuftsin derivatives as potential immunomodulators,” Polish Journal of Chemistry, 2008, 82(7):1431-1439.
[cited by applicant]
Endo et al., “Regulation of cytotoxic T lymphocyte triggering by PIR-B on dendritic cells,” Proceedings of the National Academy of Sciences of the United States of America, Sep. 23, 2008, 105(38):14515-14520.
[cited by applicant]
Engels et al., “Spectrum of cancer risk among US solid organ transplant recipients,” JAMA, 2011, 306(17):1891-1901.
[cited by applicant]
Everett et al., “Rationale and design of the cardiovascular inflammation reduction trial (CIRT): A test of the inflammatory hypothesis of atherothrombosis,” Am. Heart J., Aug. 2013, 166(2):199-207.
[cited by applicant]
Extended European Search Report for European Application No. 17790646.8, dated Nov. 25, 2019, 9 pages.
[cited by applicant]
Extended European Search Report for European Application No. 18877470.7, dated Jun. 21, 2023, 7 pages.
[cited by applicant]
Extended European Search Report for European Application No. 18880348.0, dated May 21, 2021, 7 pages.
[cited by applicant]
Extended European Search Report for European Application No. 22155443.9, dated May 20, 2022, 8 pages.
[cited by applicant]
Fantus et al., “The Ups and Downs of TORKinibs in Transplantation,” Transplantation, Aug. 2015, 99(8):e117-e118.
[cited by applicant]
Farber et al., “Immunological memory: lessons from the past and a look to the future,” Nature Reviews Immunology, 2016, 16(2):124-128.
[cited by applicant]
Fesnak et al., “Engineered T cells: the promise and challenges of cancer immunotherapy,” Nature Reviews Cancer, 2016, 16(9):566-581.
[cited by applicant]
Fourcade et al., “Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients,” Journal of Experimental Medicine, Sep. 27, 2010, 207(10):2175-2186.
[cited by applicant]
Fujimoto et al., “Synthesis of crosslinked peptidoglycan fragments for investigation of their immunobiological functions, ” Tetrahedron Letters, 2009, 50(26):3631-3634.
[cited by applicant]
Garcia et al., “Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice,” Jul. 2010, J. Clin. Invest., 120(7):2486-2496.
[cited by applicant]
Gardiner et al., “Multinational Evaluation of Mycophenolic Acid, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus Utilization,” Ann. Transplant, Jan. 5, 2016, 21:1-11.
[cited by applicant]
Garrod et al., “Murine Skin Transplantation,” Journal of Visualized Experiments, 2008, 2 pages.
[cited by applicant]
Geissmann et al., “Blood Monocytes Consist of Two Principal Subsets with Distinct Migratory Properties, ” Jul. 2003, 19:71-82.
[cited by applicant]
Gemeiner et al., “Immunomodulating Activity of 1,2-Difattyacyl-3-mercaptoglycerol Adducts,” Biological Chemistry Hoppe-Seyler, 1992, 373(11):1085-1094.
[cited by applicant]
GEO Accession No. GSE119370, “Expression data from graft infiltrating macrophages treated with mTORi-HDL nanobiologics,” Oct. 31, 2018, 2 pages.
[cited by applicant]
Guidelines for Prevention and Management of Complications Following Kidney Transplantation, Li et al. ed., Peoples Military Medical Press, Jan. 31, 2009, p. 227 (Relevance Explained in Chinese Office Action in Chinese P…
[cited by applicant]
Gummert et al. “Newer Immunosuppressive Drugs,” J Am Soc Nephrol, Jun. 1999, 10(6):1366-1380.
[cited by applicant]
Hackstein et al., “Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo,” Immunobiology, Blood, Jun. 1, 2003, 101(11):4457-463.
[cited by applicant]
Han et al., “Structural and functional properties of V156K and A158E mutants of apolipoprotein AI in the lipid-free and lipid-bound states,” Journal of Lipid Research., 2005, 46(3):589-596.
[cited by applicant]
Hancock et al., “Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection,” Proceedings of the National Academy of Sciences of the United States of America,…
[cited by applicant]
Haug et al., “A phase I trial of Immunsuppression with anti-ICAM-1 (CD54) Matrix Biology in renal allograft recipients,” Transplantation, Apr. 1993, 5594):766-773.
[cited by applicant]
Heinzelmann et al., “Endotoxin and muramyl dipeptide modulate surface receptor expression on human mononuclear cells,” Immunopharmacology, 2000, 48:117-128.
[cited by applicant]
Herrera et al., “A Novel Pathway of Alloantigen Presentation by Dendritic Cells,” The Journal of Immunology, 2004, 173:4828-4837.
[cited by applicant]
Hiroyuki et al., “Synergistic Effect of Nod1 and Nod2 Agonists with Toll-Like Receptor Agonists on Human Dendritic Cells to Generate Interleukin-12 and Helper Type 1 Cells,” American Society for Microbiology Infection a…
[cited by applicant]
Hodi et al., “Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial,” Cancer Research, 2016, 76(Issue 14_Sup…
[cited by applicant]
Hotchkiss et al., “Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy,” Nature Reviews Immunology, 2013, 13(12):862-874.
[cited by applicant]
Huang et al., “Mammalian Septins Are Required for Phagosome Formation,” Mol. Biol. Cell, Apr. 2008, 19:1717-1726.
[cited by applicant]
Iknl.nl [online], “The Netherlands Cancer Registry,” May 12, 2020, retrieved on Mar. 24, 2022, retrieved from URL<https://iknl.nl/en>, 2 pages.
[cited by applicant]
Imhof et al., “Adhesion mechanisms regulating the migration of monocytes,” Nature Reviews Immunology, Jun. 2004, 4(6):432-444.
[cited by applicant]
Inamura et al., “Synthesis of peptidoglycan fragments and evaluation of their biological activity,” Organic & Biomolecular Chemistry, 2006, 4(2):232-242.
[cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2017/030444, dated Oct. 30, 2018, 8 pages.
[cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2018/061935, dated May 26, 2020, 25 pages.
[cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2018/061939, dated May 26, 2020, 20 pages.
[cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2022/021035, mailed on Sep. 28, 2023, 9 pages.
[cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2023/065166, mailed on Sep. 29, 2023, 16 pages.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/US2017/030444, dated Sep. 22, 2017, 11 pages.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/US2018/061935, dated Apr. 19, 2019, 31 pages.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/US2018/061939, dated Feb. 22, 2019, 22 pages.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/US2022/021035, dated Jul. 25, 2022, 13 pages.
[cited by applicant]
Invitation to Pay Additional Fees in International Appln. No. PCT/US2022/021035, dated May 19, 2022, 2 pages.
[cited by applicant]
Ishida, “Synthesis and Immunoadjuvant Activity of NAcetyl-6-O-phosphono-muramoy1-1-alanyl-d-isoglutamine Methyl Ester and Its Lipophilic Derivatives,” Agricultural and Biological Chemistry, 1989, 53:1057-1063.
[cited by applicant]
Jeek et al., “Synthesis of tetrasaccharide containing glycopeptides related to bacterial cell wall starting from free tetrasaccharide by the pentafluorophenyl ester method,” Collection of Czechoslovak Chemical Communica…
[cited by applicant]
Jonas, “Reconstitution of High-Density Lipoproteins,” Methods in Enzymology, 1986, 128:553-582.
[cited by applicant]
Kanehisa et al., “KEGG for integration and interpretation of large-scale molecular data sets, ” Nucleic Acids Research, 2012, 40:D109-D114.
[cited by applicant]
Kawai et al., “Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand,” Nature Medicine, Feb. 2000, 6(2):114.
[cited by applicant]
Khalil et al., “The future of cancer treatment: immunomodulation, CARs and combination immunotherapy,” Nature Reviews Clinical Oncology, 2016, 13(5):273-290.
[cited by applicant]
Kidner et al., “Combined intralesional Bacille Calmette-Guerin (BCG) and topical imiquimod for in-transit melanoma,” Author Manuscript, J. Immunother., 2012, 35(9):716-20.
[cited by applicant]
Kim et al., “S6K1 Negatively Regulates TAK1 Activity in the Toll-Like Receptor Signaling Pathway,” Molecular and Cellular Biology, 2014, 34(3):510-521.
[cited by applicant]
Kingwell et al., “HDL-targeted therapies: progress, failures and future,” Nature Reviews Drug Discovery, 2014, 13:445-464.
[cited by applicant]
Kirk et al., “Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates,” Nature Medicine, Jun. 1999, 5(6):686-693.
[cited by applicant]
Krivorutchenko et al., “Study of the adjuvant activity of new MDP derivatives and purified saponins and their influence on HIV-1 replication in vitro,” Vaccine, 1997, 15(Dec. 2013):1479-1486.
[cited by applicant]
Kruidenier et al., “A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response,” Nature, 2012, 488(7411):404-408.
[cited by applicant]
Kuai et al., “High-Density Lipoproteins: Nature's Multifunctional Nanoparticles,” ACS Nano, 2016, 10(3):3015-3041.
[cited by applicant]
Kupel et al., “Long-term risk of pulmonary embolism in solid-organ transplant recipients,” Experimental and Clinical Transplantation, Apr. 2015, 13(Suppl 1):223-227.
[cited by applicant]
Kur'yanov et al., “Synthesis of alkyl ß-glycosides of 6-(N-acetylmuramoyl-L-alanyl-D-isoglutaminylamino)hexanoic acid and its 4-aminobutyl ester,” Chemistry of Natural Compounds, 1994, 30(3):390-394.
[cited by applicant]
Kuryanov et al., “Synthesis of muramyldipeptide lipophilic derivatives,” Bioorganicheskaya Khimiya, 1994, 20(4):439-447 (with English abstract).
[cited by applicant]
Lai et al., “Development of Luciferase Reporter-Based Cell Assays,” ASSAY and Drug Development Technologies, 2006, 4(3):307-315.
[cited by applicant]
Lameijer, “Targeting macrophage dynamics to regulate the cardiovascular immune response,” University of Amsterdam, Jan. 16, 2018,.
[cited by applicant]
Langmead et al., “Fast gapped-read alignment with Bowtie 2,” Nat. Methods, 2013, 9(4):357-359.
[cited by applicant]
Larosa et al., “The Innate Immune System in Allograft Rejection and Tolerance,” J Immunol, 2007, 178:7503-7509.
[cited by applicant]
Leeper et al., “High-Density Lipoprotein Nanoparticle Imaging in Atherosclerotic Vascular Disease,” JACC: Basic to Translational Science, 2017, 2(1):98-100.
[cited by applicant]
Leman et al., “Molecules That Mimic Apolipoprotein A-I: Potential Agents for Treating Atherosclerosis, ” J. Med. Chem., 2014, 57:2169-2196.
[cited by applicant]
Lien, “Top 10 things primary care physicians should know about maintenance immunosuppression for transplant recipients,” The American Journal of Medicine, 2015, 17 pages.
[cited by applicant]
Linsel-Nitschke et al., “HDL as a target in the treatment of atherosclerotic cardiovascular disease,” Nature Reviews Drug Discovery, 2005, 4(3):193-205.
[cited by applicant]
Liu et al., “Innate NK Cells and Macrophages Recognize and Reject Allogeneic Nonself In Vivo via Different Mechanisms,” J. Immunol., 2012, 188:2703-2711.
[cited by applicant]
Liu et al., “Insight into the Glucose Metabolism of Immune Cells in Sepsis,” Journal of Anesthesia and Perioperative Medicine, 2017, 4(1):38-44.
[cited by applicant]
Liu et al., “Rat CD8+ FOXP3+ T suppressor cells mediate tolerance to allogeneic heart transplants, inducing PIR-B in APC and rendering the graft invulnerable to rejection,” Transplant Immunology, Dec. 2004, 13:239-247.
[cited by applicant]
Liu et al., “Solid-phase synthesis of muramyl dipeptide (mdp) derivatives using a multipin method,” Bioorganic & Medicinal Chemistry Letters, 2000, 10:1361-1363.
[cited by applicant]
Loo et al., “Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity,” Clinical Cancer Research, May 21, 2012, 18(14):3834- 3845.
[cited by applicant]
Lutgens et al., “Atherosclerosis: Targeting the immune system,” ISA meeting, Amsterdam, May 23-26, 2015, 48 pages.
[cited by applicant]
Lutgens et al., “Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype,” PNAS, 2000, 97(13):7464-7469.
[cited by applicant]
Lutgens et al., “Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile,” The Journal of Experimental Medicine, 2010, 207:391-404.
[cited by applicant]
Lutgens et al., “Requirement for CD154 in the progression of atherosclerosis,” Nature Medicine, Nov. 1999, 5(11):1313-1316.
[cited by applicant]
Ma et al., “Paclitaxel Nano-Delivery Systems: A Comprehensive Review,” J Nanomed Nanotechnol., Feb. 18, 2013, 4(2): 1000164.
[cited by applicant]
Mach et al., “Reduction of atherosclerosis in mice by inhibition of CD40 signaling,” Nature, Jul. 9, 1998, 394:200-203.
[cited by applicant]
Maldonado et al., “Polymeric synthetic nanoparticles for the induction of antigen- specific immunological tolerance,” PNAS, 2014, E156-E165.
[cited by applicant]
Martner et al. Fundamentals of Practical Clinical Immunology, 1st Ed., Vinca Press, Jun. 1993, pp. 314-315 (Relevance Explained in Chinese Office Action in Chinese Patent Application No. 201880086231.5, dated Nov. 3, 20…
[cited by applicant]
Matsumoto et al., “Stimulation of nonspecific resistance to infection induced by 6-O-acyl muramyl dipeptide analogs in mice,” Infect. and Immun., 1981, 32(2):748-758.
[cited by applicant]
Maury et al., “Raised Serum Levels of Cachectin/Tumor Necrosis Factor a In Renal Allograft Rejection,” J. Exp. Med., 1987, 166:1132-1137.
[cited by applicant]
Medical Immunology, He et al. ed., Henan Science and Technology Press, Jan. 31, 1990, p. 116 (Relevance Explained in Chinese Office Action in Chinese Patent Application No. 201780041257.3, dated Dec. 3, 2020).
[cited by applicant]
Megias et al., “TLR2, TLR4 and Dectin-1 signalling in hematopoietic stem and progenitor cells determines the antifungal phenotype of the macrophages they produce,” Microbes and Infection, 2016, 18:354-363.
[cited by applicant]
Meshcheryakova et al., “Evidence for correlation between the intensities of adjuvant effects and NOD2 activation by monomeric, dimeric and lipophylic derivatives of N- acetylglucosaminyl-N-acetylmuramyl peptides,” Vacci…
[cited by applicant]
Mills et al., “Succinate Dehydrogenase Supports Metabolic Repurposing of Mitochondria to Drive Inflammatory Macrophages,” Cell, 2016, 167:457-470.
[cited by applicant]
Mitroulis et al., “Modulation of Myelopoiesis Progenitors is an Integral Component of Trained Immunity,” Cell, Jan. 2018, 172:147-161.
[cited by applicant]
Miyake et al., “Critical role of macrophages in the marginal zone in the suppression of immune responses to apoptotic cell-associated antigens,” J. Clin. Invest., Aug. 2007, 117(8):2268-2278.
[cited by applicant]
Modern Diagnosis and Therapy of Arteriosclerotic Diseases, Wei et al. ed., Jindun Publishing House, May 30, 2015, p. 598 (Relevance Explained in Chinese Office Action in Chinese Patent Application No. 201780041257.3, da…
[cited by applicant]
Mohammadi et al., “Specificity of the Transport of Lipid II by FtsW in Escherichia coli,” The Journal of Biological Chemistry, 2014, 289(21):14707-14718.
[cited by applicant]
Moore et al., “Macrophages in atherosclerosis: a dynamic balance,” Oct. 2013, 13(10):709-721.
[cited by applicant]
Moroder et al., “Synthesis of thiol-functionalized N-acetylmuramyl peptide congeners suitable for their conjugation to target molecules,” Biological Chemistry Hoppe- Seyler, 1989, 370:365-375.
[cited by applicant]
Moroi et al., “Physico-chemical properties of muroctasin,” Arzneimittel-Forschung, 1988, 38(7A):953-959.
[cited by applicant]
Morton et al., “BCG immunotherapy of malignant melanoma: summary of a seven- year experience,” Annals of Surgery, 1974, 180:635-643.
[cited by applicant]
Mudge et al., “Creating reference gene annotation for the mouse C57BL6/J genome assembly,” Mamm Genome, Jul. 18, 2015, 26:366-378.
[cited by applicant]
Mulder et al., “Therapeutic targeting of trained immunity,” Nat. Rev. Drug Discov., 2019, 18(7):553-566.
[cited by applicant]
Naesens et al., “Calcineurin Inhibitor Nephrotoxicity,” Clin. J. Am. Soc. Nephrol., 2009, 4:481-508:481-508.
[cited by applicant]
Nahrendorf et al., “The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions,” The Journal of Experimental Medicine, Nov. 26, 2007, 204(12):3037-47.
[cited by applicant]
Nakamura et al., “Rapamycin prolongs cardiac allograft survival in a mouse model by inducing myeloid-derived suppressor cells,” American Journal of Transplantation, Sep. 2015, 15(9):2364-77.
[cited by applicant]
Netea et al., “Hypothesis: stimulation of trained immunity as adjunctive immunotherapy in cancer,” Journal of Leukocyte Biology, Dec. 2017, 102:1323-1331.
[cited by applicant]
Netea et al., “Innate immune memory: a paradigm shift in understanding host defense,” Nature Immunology, 2015, 16(7):675-679.
[cited by applicant]
Netea et al., “Trained immunity: A program of innate immune memory in health and disease,” Science, Apr. 2016, 352(6284): aaf1098, 23 pages.
[cited by applicant]
Nicodeme et al., “Suppression of inflammation by a synthetic histone mimic,” Nature, 2010, 468(7327):1119-1123.
[cited by applicant]
Oberbarnscheidt et al., “Innate allorecognition,” Immunological Reviews, Mar. 2014, 258(1):145-9.
[cited by applicant]
Oberbarnscheidt et al., “Non-self recognition by monocytes initiates allograft rejection,” The Journal of Clinical Investigation, Aug. 1, 2014, 124(8):3579-89.
[cited by applicant]
Ochando et al., “Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts,” Nature Immunology, Jun. 2006, 7(6):652-62.
[cited by applicant]
Ochando et al., “Innate immune cell collaborations instigate transplant tolerance,” American Journal of Transplantation, 2014, 14:2441-2443.
[cited by applicant]
Office Action in Australian Appln. No. 2017257189, dated Feb. 28, 2022, 3 pages.
[cited by applicant]
Office Action in Australian Appln. No. 2017257189, dated Mar. 16, 2021, 6 pages.
[cited by applicant]
Office Action in Australian Appln. No. 2018370237, mailed on Oct. 20, 2023, 6 pages.
[cited by applicant]
Office Action in Canadian Appln. No. 3021645, mailed on Jul. 13, 2023, 5 pages.
[cited by applicant]
Office Action in Chinese Appln. No. 201580085777.5, dated Jan. 19, 2021, 15 pages (with English Translation).
[cited by applicant]
Office Action in Chinese Appln. No. 201580085777.5, dated Jul. 3, 2020, 13 pages (with English Translation).
[cited by applicant]
Office Action in Chinese Appln. No. 201780041257.3, dated Apr. 15, 2022, 31 pages (with English Translation).
[cited by applicant]
Office Action in Chinese Appln. No. 201780041257.3, dated Dec. 3, 2020, 26 pages (with English Translation).
[cited by applicant]
Office Action in Chinese Appln. No. 201780041257.3, dated Oct. 18, 2021, 34 pages (with English Translation).
[cited by applicant]
Office Action in Chinese Appln. No. 201880086231.5, dated Jan. 28, 2022, 23 pages (with English Translation).
[cited by applicant]
Office Action in Chinese Appln. No. 201880086231.5, dated May 29, 2023, 21 pages (with English Translation).
[cited by applicant]
Office Action in Chinese Appln. No. 201880086231.5, dated Nov. 3, 2022, 24 pages (with English Translation).
[cited by applicant]
Office Action in Chinese Appln. No. 201880087082.4, dated Apr. 13, 2022, 17 pages (with English Translation).
[cited by applicant]
Office Action in Chinese Appln. No. 201880087082.4, dated Jan. 12, 2023, 9 pages (with English Translation).
[cited by applicant]
Office Action in Chinese Appln. No. 201880087082.4, dated Jun. 14, 2023, 10 pages (with English translation).
[cited by applicant]
Office Action in Japanese Appln. No. 2018-556339, dated Feb. 1, 2022, 6 pages (with English Translation).
[cited by applicant]
Office Action in Japanese Appln. No. 2018-556339, dated Nov. 22, 2022, 6 pages (with English Translation).
[cited by applicant]
Office Action in Japanese Appln. No. 2020-545063, dated Nov. 15, 2022, 9 pages (with English Translation).
[cited by applicant]
Office Action in Japanese Appln. No. 2020-545063, mailed on Jul. 3, 2023, 6 pages (with English translation).
[cited by applicant]
Office Action in Japanese Appln. No. 2020-545065, dated Nov. 22, 2022, 7 pages (with English Translation).
[cited by applicant]
Office Action in United States U.S. Appl. No. 18/121,527, mailed on Oct. 6, 2023, 10 pages.
[cited by applicant]
Organ Transplantation, Yuyuan Liu ed., Human Science and Technology Press, Oct. 31, 2009, p. 52 (Relevance Explained in Chinese Office Action in Chinese Patent Application No. 201780041257.3, dated Dec. 3, 2020).
[cited by applicant]
Pahl et al., “Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-y,” J Exp Clin Cancer Res. 2014; 33:2…
[cited by applicant]
Paolicelli et al., “Surface-modified PLGA-based Nanoparticles that can Efficiently Associate and Deliver Virus like Particles,” Nanomedicine, Aug. 24, 2010, 5(6):843-853.
[cited by applicant]
Pardoll et al., “The blockade of immune checkpoints in cancer immunotherapy,” Nature Reviews Cancer, 2012, 12(4):252-264.
[cited by applicant]
Pardoll, “Immunology beats cancer: a blueprint for successful translation,” Nat. Immunol., 2012, 13(12):1129-1132.
[cited by applicant]
Pérez-Medina et al., “In vivo PET imaging of HDL in multiple atherosclerosis models,” JACC: Cardiovascular Imaging, Aug. 2016, 9(8):950-61.
[cited by applicant]
Pérez-Medina et al., “Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy,” Nature Communications, 2016, 7:11838.
[cited by applicant]
Pérez-Medina et al., “PET imaging of tumor-associated macrophages with 89Zr- labeled high-density lipoprotein nanoparticles,” Journal of Nuclear Medicine, Aug. 2015, 56(8):1272-7.
[cited by applicant]
Potteaux et al., “Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe / mice during disease regression,” The Journal of Clinical Investigation, May 2, 2011, 121(5):2025-36.
[cited by applicant]
Priem et al., “Trained Immunity-Promoting Nanobiologic Therapy Suppresses Tumor Growth and Potentiates Checkpoint Inhibition,” Cell 2020, 183:786-801.
[cited by applicant]
Pritchard, “Sourcing a chemical succession for cyclosporin from parasites and human pathogens,” Drug Discovery Today, May 2005, 10(10):688-691.
[cited by applicant]
PubChem [Online], “SID 40944914,” Dec. 5, 2007, [Retrieved on Aug. 9, 2022], retrieved from URL<https://pubchem.ncbi.nlm.nih.gov/substance/40944914>, 5 pages.
[cited by applicant]
Pullen et al., “CD40-tumor necrosis factor receptor-associated factor (TRAP) interactions: regulation of CD40 signaling through multiple TRAP binding sites and TRAP hetero-oligomerization,” Biochemistry, 1998, 37:11836-…
[cited by applicant]
Ramos-Cabrer et al., “The effect of loading nascent HDL with gadolinium phospholipids in the structural stability of the particles,” Proceedings of the International Society for Magnetic Resonance in Medicine, 2014, 22(…
[cited by applicant]
Ridker et al., “Interleukin-1ß inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS),” American Heart Journal, Oct…
[cited by applicant]
Ritchie et al., “limma powers differential expression analyses for RNA-sequencing and microarray studies,” Nucleic Acids Research, Apr. 20, 2015, 43(7):e47-, 13 pages.
[cited by applicant]
Robbins et al., “Local proliferation dominates lesional macrophage accumulation in atherosclerosis,” Nature Medicine, Sep. 2013, 19(9): 1166-1172, 15 pages.
[cited by applicant]
Saeed et al., “Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity,” Science, 2014, 345(6204):1251086.
[cited by applicant]
Sakuishi et al., “Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity,” Journal of Experimental Medicine, Sep. 27, 2010, 207(10):2187-2194.
[cited by applicant]
Sanchez-Gaytan et al., “HDL-mimetic PLGA nanoparticle to target atherosclerosis plaque macrophages,” Author Manuscript, Bioconjug. Chem., 2015, 26(3):443-451.
[cited by applicant]
Sanchez-Gaytan et al., “Real-Time Monitoring of Nanoparticle Formation via FRET Imaging,” Author Manuscript, Angewandte Chemie International Edition, 2017, 56(11):2923-2926.
[cited by applicant]
Schönbeck et al., “CD40 signaling and plaque instability,” Circulation Research, Dec. 7, 2001, 89(12):1092-103.
[cited by applicant]
Schönbeck et al., “Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice,” Proceedings of the National Academy of Sciences, Jun. 20, 2000, 97(13):7458-7463.
[cited by applicant]
Schwarz et al.“Identification of differentially expressed genes induced by transient ischemic stroke,” Brain Res Mol Brain Res, 2002; 101(1-2):12-22.
[cited by applicant]
Scientificamerican.com [online], “Cancer Immunotherapy: The Cutting Edge Gets Sharper,” Oct. 1, 2015, retrieved on Mar. 24, 2022, retrieved from URL<https://www.scientificamerican.com/article/cancer-immunotherapy-the-cu…
[cited by applicant]
Segrest et al., “The Amphipathic a Helix: A Multifunctional Structural Motif in Plasma Apolipoproteins,” Advances in Protein Chemistry, 1994, 45:303-369.
[cited by applicant]
Shah et al., “Effects of recombinant apolipoprotein A-IMilano on aortic atherosclerosis in apolipoprotein E-deficient mice, ” Circulation, Mar. 3, 1998, 97(8):780-5.
[cited by applicant]
Shi et al., “Monocyte recruitment during infection and inflammation,” Nature Reviews Immunology, Nov. 2011, 11(11): 762-74.
[cited by applicant]
Shimizu et al., “Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis,” The Journal of Immunology, Se…
[cited by applicant]
Shuchman, “Trading restenosis for thrombosis? New questions about drug-eluting stents,” New England Journal of Medicine, Nov. 9, 2006, 355(19): 1949-52.
[cited by applicant]
Skajaa et al., “High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30(2):169-176.
[cited by applicant]
Skajaa et al., “The biological properties of iron oxide core high-density lipoprotein in experimental atherosclerosis,” Biomaterials, 2011, 32:206-213.
[cited by applicant]
Song et al., “Immune Training Unlocks Innate Potential,” Cell, Jan. 11, 2018, 172:3-5.
[cited by applicant]
Sporri et al., “Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function,” Nature immunology, 2005, 6:163-170.
[cited by applicant]
Stone et al., “A prospective natural-history study of coronary atherosclerosis,” New England Journal of Medicine, Jan. 20, 2011, 364(3):226-35.
[cited by applicant]
Sun et al., “Interactions of NIPAM nanogels with model lipid multi-bilayers: A neutron reflectivity study,” Journal of Colloid and Interface Science, 2018, 536:598- 608.
[cited by applicant]
Swirski et al., “Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure,” Science, Jan. 11, 2013, 339(6116): 161-6.
[cited by applicant]
Swirski et al., “Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata,” The Journal of Clinical Investigation, Jan. 2, 2007, 117(1): 195-205.
[cited by applicant]
Swirski et al., “Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease,” Proceedings of the National Academy of Sciences of the United States of America, Jul. 5, 2006, 103(27)…
[cited by applicant]
Swirski et al., “Myeloperoxidase-rich Ly-6C+ myeloid cells infiltrate allografts and contribute to an imaging signature of organ rejection in mice,” The Journal of Clinical Investigation, Jul. 1, 2010, 120(7):2627-34.
[cited by applicant]
Tang et al., “Immune cell screening of a nanoparticle library improves atherosclerosis therapy,” PNAS, Oct. 2016, 113(44):E6731-E6740.
[cited by applicant]
Tang et al., “Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation,” Science Advances, Apr. 1, 2015, 1(3):e1400223, 10 pages.
[cited by applicant]
Tehranirokh et al., “Microfluidic devices for cell cultivation and proliferation,” Biomicrofluidics, 2013, 7:51502.
[cited by applicant]
Tenahrench et al., “The Basic and Clinical of Coliform Cancer,” 1st Ed., Shanghai Scientific and Technical Literature Press, Sep. 1999, pp. 252-253 (Relevance Explained in Chinese Office Action in Chinese Patent Applica…
[cited by applicant]
Thomson et al., “Immunoregulatory functions of mTOR inhibition,” Nature Reviews Immunology, May 2009, 9(5):324-37.
[cited by applicant]
Transplantatiestichting.nl [online], “Cijfers over donatie en transplantatie,” available on or before Mar. 2020, retrieved on Mar. 24, 2022, retrieved from URL<https://www.transplantatiestichting.nl/publicaties-en-nasla…
[cited by applicant]
Unos.org [online], “Data,” Nov. 2002, retrieved on Mar. 24, 2022, retrieved from URL<https://unos.org/data/>, 3 pages.
[cited by applicant]
Valenta et al., “Macrophage PLTP is atheroprotective in LDLr-deficient mice with systemic PLTP deficiency,” Journal of Lipid Research, Jan. 1, 2008, 49(1):24-32.
[cited by applicant]
Van den Berg et al., “Blocking CD40-TRAF6 interactions by small-molecule inhibitor 6860766 ameliorates the complications of diet-induced obesity in mice,” International Journal of Obesity, May 2015, 39(5):782-90.
[cited by applicant]
Van der Valk et al., “Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration,” Author Manuscript, Nanomedicine, 2015, 11:1039-1046.
[cited by applicant]
Vanneman et al., “Combining immunotherapy and targeted therapies in cancer treatment,” Nature Reviews Cancer, 2012, 12(4):237-251.
[cited by applicant]
Vannieuwenhze et al., “The total synthesis of lipid I,” J. Am. Chem. Soc., 2001, 123:6983-6988.
[cited by applicant]
Vugts et al., “Synthesis of Phosphine and Antibody—Azide Probes for in Vivo Staudinger Ligation in a Pretargeted Imaging and Therapy Approach,” Bioconjugate Chem., 2011, 22:2072-2081.
[cited by applicant]
Wang et al., “Glycan sequence-dependent Nod2 activation investigated by using a chemically synthesized bacterial peptidoglycan fragment library,” ChemBioChem, 2013, 14:482-488.
[cited by applicant]
Wang et al., “GO-function: deriving biologically relevant functions from statistically significant functions,” Briefings in Bioinformatics, Mar. 1, 2012, 13(2):216-27.
[cited by applicant]
Wang et al., “Peptidoglycan microarray as a novel tool to explore protein-ligand recognition,” Biopolymers (Pept. Sci.), 2016, 106(4):422-429.
[cited by applicant]
Wang et al., “Synthesis of characteristic Mycobacterium peptidoglycan (PGN) fragments utilizing with chemoenzymatic preparation of meso-diaminopimelic acid (DAP), and their modulation of innate immune responses,” Organi…
[cited by applicant]
Wasan et al., “Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery,” Nature Review Drug Discovery, 2008, 7:84-99.
[cited by applicant]
Wells et al., “Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance,” Nature Medicine, Nov. 1999, 5(11):1303-7.
[cited by applicant]
Willems et al., “Lipophilic Muramyl Dipeptide-Antigen Conjugates as Immunostimulating Agents,” ChemMedChem Communications, 2016, 11:190-198.
[cited by applicant]
Wu et al., “Homeostatic proliferation is a barrier to transplantation tolerance,” Nature Medicine, Jan. 2004, 10(1):87-92.
[cited by applicant]
Yan et al., “Indexing TNF-a gene expression using a gene-targeted reporter cell line,” BMC Biology, 2009, 7:8.
[cited by applicant]
Yang et al., “Rapamycin-conditioned dendritic cells induced immune tolerance through the regulation of Treg/Th17 cells in mice,” Natl. Med. J. China, 2015, 95(30):2469-2473 (with English Abstract).
[cited by applicant]